Delving into the Latest Updates on Eltrombopag Diolamine with Synapse

RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Australia)

Login to view timeline

Structure/Sequence

Molecular FormulaC29H36N6O6

InChIKeyPLILLUUXAVKBPY-SBIAVEDLSA-N

CAS Registry496775-62-3

Background:
X-Linked Chronic Granulomatous Disease (X-CGD) is caused by a gene mutation that makes the immune system to not work properly. Researchers want to see if a lentiviral gene transfer treatment will have the ability to make the patient s immune system more normal, in particular reduce the risk of CGD related infections. The gene transfer takes a person s own stem cells, cultures them to put the normal gene in, then gives the cells back to the person.
Objective:
To test a gene transfer treatment for X-CGD.
Eligibility:
Participants aged 3-60 with X-CGD
Design:
Participants will be screened under protocol 05-I-0123. They will undergo:
Medical history
Physical exam
Heart tests
Imaging tests, as needed
Blood tests
Lung function tests, as needed
Dental and audiology exams, if needed
Quality of life questionnaire
Bone marrow aspiration. A needle will be inserted into the hip bone or breastbone to collect bone marrow.
Some screening tests will be repeated during the study.
Participants will have an apheresis procedure under protocol 94-I-0073. Stem cells will be collected.
Participants will get a series of drugs to prepare them for the gene transfer.
Participants will stay at the NIH Clinical Center for a little over a month. They will get a central line. It is a large intravenous (IV) catheter that is placed into a vein of the neck, chest, or arm. They will get chemotherapy and their corrected stem cells through their IV line.
Participants will have 12 follow-up outpatient visits in the 2 years after their gene transfer, as well as visits with their local doctor. Then they will enroll in another study for long-term follow-up visits that will last for 13 years.

Start Date19 Aug 2025

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

NCT07093606

/ RecruitingNot ApplicableIIT

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Start Date14 Jul 2025

Sponsor / Collaborator

Sohag University

100 Clinical Results associated with Eltrombopag Diolamine

Login to view more data

100 Translational Medicine associated with Eltrombopag Diolamine

Login to view more data

100 Patents (Medical) associated with Eltrombopag Diolamine

Login to view more data

1,549

Literatures (Medical) associated with Eltrombopag Diolamine

31 Dec 2025·Hematology

Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: A series of four case reports

Article

Author: Ghanima, Waleed ; Rackwitz, Stefan ; Lucas Boronat, Francisco Javier ; Carrai, Valentina

INTRODUCTION:

A goal of most primary immune thrombocytopenia (ITP) treatments is reducing or discontinuing treatment while maintaining a response including an absence of bleeding events. We present four cases describing treatment with the spleen tyrosine kinase (SYK) inhibitor, fostamatinib, that showed sustained response off treatment (SROT).

CASE PRESENTATIONS:

Case 1 was a 66-year-old male with chronic ITP. He was pre-treated with prednisone and rituximab before being in the FIT-2 clinical trial (placebo). He received fostamatinib in the FIT-3 open-label extension for seven weeks and maintained SROT for 2.5 years. Case 2 was a 54-year-old female patient with chronic, highly refractory ITP. SROT was achieved after 6 months of fostamatinib and was maintained for more than 16 months (in remission to date). Case 3 was a 60-year-old male with chronic ITP. He was successfully treated with cycles of corticosteroids for six years prior to fostamatinib. He was treated with fostamatinib plus prednisone for approximately two months. SROT was observed in this patient for one year. Case 4 was a 67-year-old male with persistent ITP. Before fostamatinib, he was unresponsive to high-dose dexamethasone, IVIG, eltrombopag and romiplostim. After 11 months of fostamatinib, his dose was tapered for three months and ultimately discontinued. SROT was observed for more than ten months (in remission to date).

DISCUSSION:

These cases emphasize that SROT is achievable with fostamatinib in complex ITP cases unresponsive to multiple previous therapies. Additional research is needed to identify the magnitude of the underlying mechanisms, and the clinical factors associated with, and potentially predictive of, SROT.

31 Dec 2025·PLATELETS

A case with a novel GATA1 variant mimicking immune thrombocytopenia attacks

Article

Author: Aktekin, Elif Habibe ; Ceylaner, Serdar ; Erbay, Ayşe ; Beşen, Şeyda ; Yazıcı, Nalan

One of the leading thrombocytopenia occasions in childhood is immune thrombocytopenia (ITP). Small number of these patients do not respond to treatment methods known to be effective for ITP such as corticosteroids, intravenous immunoglobulin and thrombopoietin receptor agonists (eltrombopag, romiplostim, etc.) and have serious bleeding symptoms. We present a case in which a molecular genetic analysis was performed due to challenging responses to medical treatment for severe systemic bleeding symptoms which were similar to ITP. A hemizygous variant was detected in the GATA1 gene and a homozygous variant in the ATP2A1 gene for Brody myopathy. Eltrombopag, romiplostim, IVIG and corticosteroid were applied to resistant thrombocytopenia of the patient without knowing the cause. Patient had response in platelet counts in some occasions. This situation attracted our attention after the detection of this GATA variant in the etiopathogenesis of thrombocytopenia. Further investigations should be performed for much more rare causes of thrombocytopenia in patients with refractory thrombocytopenia attacks.

01 Nov 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Effect of eltrombopag on biochemical assay parameters

Article

Author: Yamashita, Naoki ; Goto, Hideki ; Kojima, Kazushige ; Teshima, Takanori ; Seimiya, Masanori ; Nakano, Keiichi

Eltrombopag, which is used to treat thrombocytopenia, causes bilirubin-like yellowish-brown serum discoloration and interferes with biochemical parameter measurements. However, the extent of these interferences and the methods and reagents involved remain unclear. Although previous studies have examined the effects of eltrombopag on bilirubin measurements, its effect on enzymatic measuring of bilirubin levels, which is widely used in Japan, has been limited. Serum samples were collected from 17 eltrombopag-receiving patients. Eltrombopag was added to drug-free serum samples at concentrations ranging from 2.5 to 40.0 µg/mL. The light absorption spectra of the samples were recorded. The lipemia index and 21 biochemical parameters, including total bilirubin (TB) levels, measured by enzymatic, vanadate, and Doumas methods were analyzed. The addition of eltrombopag resulted in a concentration-dependent yellowish-brown discoloration of the serum samples and an increase in absorbance from 340 to 640 nm. The lipemia index significantly increased with increasing eltrombopag concentrations. Fourteen patients displayed triglyceride values below 2.60 mmol/L, one of whom exceeding the lipemia index threshold and exhibiting a yellowish-brown serum with an absorbance increase from 340 to 640 nm. The TB measurements showed a statistically significant positive bias across all three methods, with varying degrees of interference: enzymatic (280.2 %), vanadate (124.6 %), and Doumas (323.9 %) at 40.0 µg/mL eltrombopag. Moreover, uric acid levels showed a statistically significant, concentration-dependent negative bias. This study provides valuable insights into eltrombopag interference, offering well-defined methodological details to assist clinical laboratories in accurately interpreting the patient results.

22

News (Medical) associated with Eltrombopag Diolamine

12 Aug 2025

·pipelinereview.com

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

BASEL, Switzerland I August 12, 2025 I Novartis today announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids 1,2 . Ianalumab plus eltrombopag, compared to placebo plus eltrombopag, significantly prolonged the time to treatment failure (TTF), the primary endpoint that assesses how long patients maintain safe platelet levels during and after the treatment period 1,2 . Ianalumab is being investigated in other B cell-driven autoimmune diseases, including ongoing Phase III trials in first-line ITP and in second and later lines of warm autoimmune hemolytic anemia, with readouts expected in 2026 3,4 . In VAYHIT2, patients treated with ianalumab plus eltrombopag experienced a significantly higher rate of sustained improvements in platelet count at six months, the key secondary endpoint of the study 1 . The safety profile of ianalumab was consistent with what was previously observed in clinical studies, with no new safety signals 1 . “While current treatments for ITP are generally effective in raising platelet counts, many patients require life-long treatment to maintain safe levels, which can create a lasting treatment burden,” said Adam Cuker, M.D., Professor of Medicine and Chief, Section of Hematology, University of Pennsylvania. “The results from VAYHIT2 are encouraging, as they suggest that ianalumab may support longer periods of disease control and reduce the need for continuous treatment.” ITP is a rare autoimmune disorder characterized by low platelet counts leading to an increased risk of bleeding, bruising and chronic fatigue 5-7 . Many people living with ITP cycle through multiple therapies, unable to achieve long-term disease control 7 . There is a need for other treatment options with novel mechanisms of action that offer durable responses while reducing the burden of long-term treatment 8 . “For many people living with ITP, chronic treatment can disrupt their daily life due to the burden of regular dosing, dose adjustments and side effects,” said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer, Novartis. “These positive top-line results from the Phase III study highlight the potential of ianalumab, if approved, to deliver long-term disease control with four once-monthly doses and enable extended time off treatment.” Data is expected to be presented at an upcoming medical meeting and included in future regulatory submissions in 2027 along with results from the ongoing first-line ITP trial, VAYHIT1. Ianalumab has been granted Orphan Drug Designation by the US Food and Drug Administration and the European Medicines Agency 9,10 . Recently, Novartis announced positive top-line results for ianalumab in adults with active Sjögren’s disease. About ianalumab Ianalumab (VAY736) is a novel fully human monoclonal antibody being investigated for its potential to treat various B cell-driven autoimmune diseases, including Sjögren’s disease, immune thrombocytopenia (ITP), systemic lupus erythematosus (SLE), lupus nephritis (LN), warm autoimmune hemolytic anemia (wAIHA) and diffuse cutaneous systemic sclerosis (dcSSc) 2,4,11-16 . Its mechanism of action targets B cells in two ways, namely combining B cell depletion via antibody-dependent cellular toxicity (ADCC) and interruption of BAFF-R mediated signals of B cell function and survival 11 . In clinical trials, ianalumab showed promising efficacy and a favorable safety profile in Sjögren’s disease, systemic lupus erythematosus, and immune thrombocytopenia 17-19 . Ianalumab originates from an early collaboration with MorphoSys AG, a company which Novartis later acquired in 2024 20 . About primary immune thrombocytopenia Primary immune thrombocytopenia (ITP) is a rare, autoimmune disorder in which the immune system mistakenly targets and destroys platelets, the cells essential for blood clotting 5 . This can lead to symptoms such as prolonged bleeding, easy bruising and chronic fatigue, which can significantly impact daily life 5,6 . Despite available treatments, many people living with ITP cycle through multiple therapies, unable to achieve long-term disease control 7 . Current options often focus on maintaining safe platelet levels and preventing bleeding complications and may require ongoing use 7,21 . The burden of chronic treatment and unpredictability of relapses can significantly impact quality of life 6,22 . There is a need for therapies that offer durable response while reducing the burden of long-term treatment 8 . About VAYHIT2 VAYHIT2 (NCT05653219) is a Phase III, multi-center, randomized, double-blind study evaluating the efficacy and safety of two different doses of ianalumab versus placebo, in addition to eltrombopag, in adults with primary immune thrombocytopenia (ITP) (platelet count <30 G/L) who failed previous first-line treatment with corticosteroids 2 . Alongside eltrombopag, patients were randomized 1:1:1 to receive four once-monthly intravenous infusions of ianalumab at 3 mg/kg, ianalumab at 9 mg/kg or placebo 2 . The primary endpoint was time to treatment failure, which is defined as the time from randomization until either: a platelet count of less than 30 G/L later than 8 weeks from randomization; the need for rescue therapy later than 8 weeks from randomization; initiation of a new ITP treatment at any time; ineligibility or inability to taper/discontinue eltrombopag; or death 2 . The key secondary endpoint is the percentage of patients with a stable platelet count response at Month 6 2 . Other secondary endpoints include measures of depth and duration of platelet response as well as patient-reported outcomes that measure quality of life and fatigue, among other endpoints 2 . About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . References SOURCE: Novartis

Clinical ResultPhase 3ImmunotherapyOrphan Drug

12 Aug 2025

·www.fiercebiotech.com

Novartis\' blood disorder readout earns Novartis 3rd phase 3 win for ianalumab this week

Primary immune thrombocytopenia is an autoimmune disorder characterized by a low platelet count.\n For Novartis, this week is all about ianalumab. A day after posting a pair of phase 3 wins for the tricky indication of Sjögren\'s syndrome, the Swiss pharma has unveiled a separate late-stage victory in another B-cell-driven autoimmune disease.The latest clinical success comes from a phase 3 study of two different doses of ianalumab, a dual-mechanism, B-cell-depleting antibody that targets the protein BAFF-R, in patients with a low platelet count disorder called primary immune thrombocytopenia (ITP). Participants also received Novartis\' thrombocytopenia drug Promacta as part of their treatment and had found that corticosteroids hadn’t resolved their condition.While Novartis didn’t dig into the data, the company confirmed that treatment with ianalumab plus eltrombopag “significantly prolonged” the time to treatment failure (TTF) when compared to patients who received Promacta alone, hitting the trial’s primary endpoint. TTF measures how long patients maintain safe platelet levels during and after treatment.When it came to a key secondary endpoint, the ianalumab-eltrombopag treatment also showed a “significantly higher” rate of sustained improvements in platelet count at six months, Novartis explained in an Aug. 12 release.Ianalumab is administered as four once-monthly doses to treat ITP. Novartis is touting the therapy as potentially offering “long-term disease control through a short course of treatment” that could “allow patients extended time off treatment.”This would help it stand out from the current crop of ITP therapies, which often require lifelong treatment.“For many people living with ITP, chronic treatment can disrupt their daily life due to the burden of regular dosing, dose adjustments and side effects,” Novartis Chief Medical Officer Shreeram Aradhye, M.D., said in the release. “These positive topline results from the phase 3 study highlight the potential of ianalumab, if approved, to deliver long-term disease control with four once-monthly doses and enable extended time off treatment.”Ianalumab\'s story begins with Novartis’ collaboration with MorphoSys, before the Big Pharma went on to buy the biotech last year. The pharma is currently eyeing 2027 for an approval application for ianalumab in ITP, for which it hopes to combine data from this morning’s study with an ongoing trial of the drug as a first-line treatment for the disorder. In the meantime, the company is expecting phase 3 readouts for ianalumab in other B-cell-driven autoimmune diseases next year, such as warm autoimmune hemolytic anemia.This morning’s late-stage win in ITP comes just a day after Novartis reported a pair of phase 3 successes in Sjögren\'s syndrome, an autoimmune disorder that has defeated some of the company’s peers. Novartis hailed the triumph yesterday as the “first ever global phase 3 trials to demonstrate statistically significant reduction in disease activity for Sjögren\'s disease.”Ianalumab hasn’t always been so lucky in the clinic. Only last month, the company reported that the B-cell-depleting antibody had failed to hit the efficacy threshold in a phase 2 study for a painful skin condition called hidradenitis suppurativa.

$Novartis\' blood disorder readout earns Novartis 3rd phase 3 win for ianalumab this week$

Phase 3Phase 2Clinical Result

12 Aug 2025

·firstwordpharma.com

Novartis’ ianalumab notches another Phase III win, now in ITP

Just a day after conquering a pair of pivotal trials in Sjögren's disease, Novartis had more good news to share about ianalumab. The company announced Tuesday that the investigational B cell-targeted monoclonal antibody — given on top of the thrombopoietin receptor agonist eltrombopag — met the primary and key secondary goals of a Phase III study in corticosteroid-refractory primary immune thrombocytopenia (ITP).The VAYHIT2 study enrolled 153 adults with primary ITP and platelet counts below 30 G/L following corticosteroid treatment failure, who were randomised to receive four monthly intravenous infusions of ianalumab at 3 mg/kg or 9 mg/kg doses, or placebo, alongside eltrombopag therapy. The primary endpoint measured time from randomisation to treatment failure, defined as platelet count < 30 G/L after 8 weeks, need for rescue therapy after 8 weeks, new ITP treatment at any time, inability to taper/stop eltrombopag, or death.Top-line findings showed that ianalumab, on top of eltrombopag, met the study’s main efficacy goal, maintaining safe platelet levels for prolonged periods during and after treatment versus the placebo plus eltrombopag regimen. Additionally, a key secondary endpoint was achieved, with the ianalumab arm demonstrating significantly higher rates of sustained platelet count improvements at six months compared with the placebo arm. “These…results…highlight the potential of ianalumab, if approved, to deliver long-term disease control with four once-monthly doses and enable extended time off treatment,” said Shreeram Aradhye, chief medical officer at Novartis.Safety-wise, ianalumab’s profile remained consistent with previous studies, with no new safety signals identified. Novartis is also testing the antibody in the Phase III VAYHIT1 trial for first-line ITP, with results due next year, and plans regulatory filings in 2027 backed by data from VAYHIT1 and VAYHIT2.Besides, ITP and Sjögren's disease, ianalumab — gained by the Swiss drugmaker via last year's buyout of MorphoSys — is being studied across a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, warm autoimmune haemolytic anaemia and diffuse cutaneous systemic sclerosis. The company recently halted the biologic’s further development in hidradenitis suppurativa after a mid-stage study missed its target criteria for efficacy.

Phase 3Clinical Result

100 Deals associated with Eltrombopag Diolamine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Eltrombopag Diolamine	B02BX05	DB06210

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Heparin-induced thrombocytopenia	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	12 Sep 2024
Anemia, Aplastic	European Union	Novartis Europharm Ltd.	11 Mar 2010
Anemia, Aplastic	Iceland	Novartis Europharm Ltd.	11 Mar 2010
Anemia, Aplastic	Liechtenstein	Novartis Europharm Ltd.	11 Mar 2010
Anemia, Aplastic	Norway	Novartis Europharm Ltd.	11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic	European Union	Novartis Europharm Ltd.	11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic	Iceland	Novartis Europharm Ltd.	11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic	Liechtenstein	Novartis Europharm Ltd.	11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic	Norway	Novartis Europharm Ltd.	11 Mar 2010
Thrombocytopenia	United States	Novartis Pharmaceuticals Corp.	20 Nov 2008

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Phase 3	Taiwan Province	Novartis AG	01 Mar 2014
Contusions	Phase 3	United States	GSK Plc	01 Mar 2012
Contusions	Phase 3	Argentina	GSK Plc	01 Mar 2012
Contusions	Phase 3	Czechia	GSK Plc	01 Mar 2012
Contusions	Phase 3	Germany	GSK Plc	01 Mar 2012
Contusions	Phase 3	Hong Kong	GSK Plc	01 Mar 2012
Contusions	Phase 3	Israel	GSK Plc	01 Mar 2012
Contusions	Phase 3	Italy	GSK Plc	01 Mar 2012
Contusions	Phase 3	Poland	GSK Plc	01 Mar 2012
Contusions	Phase 3	Russia	GSK Plc	01 Mar 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03939637 (CTgov)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	122	Eltrombopag (Experimental: Eltrombopag)	lcwqimlyqo = ybsovgmcfe xgwhzazkla (lewndpphrb, jngkmuckrl - opidwzbqxr) View more	-	29 Jul 2025
				anti-D immunoglobulin (Comparator: Standard Therapy)	lcwqimlyqo = dllskgcpdk xgwhzazkla (lewndpphrb, ihwnmsbumx - yeqdztgnbm) View more
NCT04328727 (REACTS, CTgov)	Phase 2	Anemia, Aplastic \| Refractory Severe Aplastic Anemia	36	rabbit anti-thymocyte globulin+cyclosporine A+Eltrombopag	rzjtqwgedv = uvhgeksszl zahmmsexiq (zppoovhszk, uxdirtreml - dysmahvwwz) View more	-	17 Jul 2025
EHA2025 Manual	Not Applicable	Hepatitis \| Anemia, Aplastic	17	Total	fksxszdjyg(ebheegdxgl) = mojifrgmkw fzswwijzml (anirtxtoti ) View more	Positive	12 Jun 2025
				Avatrombopag	fksxszdjyg(ebheegdxgl) = vezougwywe fzswwijzml (anirtxtoti ) View more
EHA2025	Not Applicable	Thrombosis	267	Eltrombopag	jojtftkqxo(jjwutotggy) = Among the 35 vascular AEs observed in 31 patients, 51% were arterial and 49% were venous, including embolism and deep vein thrombosis fxwqmxgcer (bolpzvedaa )	-	14 May 2025
				Romiplostim
REAL-AVA 2.0 (EHA2025)	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	79	Eltrombopag	rawzoxvpch(jimsfwafkf) = rmycfanbfq qkclqjggap (snfcclwtfa ) View more	Positive	14 May 2025
				Romiplostim	rawzoxvpch(jimsfwafkf) = kklpnswpoy qkclqjggap (snfcclwtfa ) View more
EHA2025	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	267	Romiplostim	mohflvbzww(jffktjsdnw) = whpkecdfyn yeeeotcbdv (fwiszbacpd ) View more	-	14 May 2025
				Eltrombopag	ncknaqeebg(zwqnvsbygx) = vwwdrgdhxg idbmlfvbfj (twlstroant ) View more
NCT04346654 (XPAG-ITP, CTgov)	Phase 2	Purpura, Thrombocytopenic, Idiopathic	26	Eltrombopag+Dexamethasone (Eltrombopag + Dexamethasone)	pxwfdrxcbx = rdrihatzpi nhizexhwqw (oxlpgpmqjr, vbuuvnsqwq - ojhrjbatvd) View more	-	17 Mar 2025
				Dexamethasone (Dexamethasone)	pxwfdrxcbx = qgbtsauwzv nhizexhwqw (oxlpgpmqjr, iwgedrvucd - nntcbprkqy) View more
NCT03988608 (CTgov)	Phase 2	Anemia, Aplastic \| Refractory Severe Aplastic Anemia	20	Eltrombopag	aykhrfxvlt = qudrxkidmo dyogomkzyh (jjokrkytmx, mdaogsjuxs - fnxkdgcldp) View more	-	03 Feb 2025
ASH2024 Manual	Phase 2	Purpura, Thrombocytopenic, Idiopathic First line	23	Low-Dose Corticosteroids (LD-CIS) + Low-Dose Eltrombopag (LD-EPAG)	jvjsgowadx(djickboqoj) = riodhesaou pjpweegirv (nybnqggixn ) View more	Positive	09 Dec 2024
NCT03939637 (ASH2024)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	-	Eltrombopag	huceseioxr(guashldbtr) = 20 AEs grade 3 or higher (including 6 SAEs) in the epag arm, and 6 (3 SAEs) in the SOC arm during the first 12 weeks. The most common AEs were headache (3 epag, 3 SOC) and epistaxis (1 epag, 2 SOC). Drug-related SAEs occurred in 6 pts (epag - 2 elevated LFTs, 2 headache (HA); SOC - 1 allergic reaction, 1 HA). There were no thromboembolic events. There was 1 intracranial hemorrhage in the epag arm. ywyirgaejo (eetihvpvgq )	-	09 Dec 2024
				Standard First-Line Therapy (SOC)